$RichWire Markets and money, explained simply

LIVE

08:46 Credo Technology Shares Fall Sharply Following September Earnings Report 08:35 Artificial Intelligence Dominates Market Focus Once Again 08:29 Nvidia Shares Slide as CEO Jensen Huang Resigns Following Scandal 08:25 Embraer Maintains Buy Rating Following Third-Quarter Performance 08:23 Anthropic Targets $1.4 Trillion Valuation in Upcoming Nasdaq Debut 08:20 Lowe's Positioned for Growth Amid Expanding Home Remodeling Budgets 07:39 Examining OMS Energy Technologies: Balance Sheet Strength and Growth Prospects 07:35 NextEra Energy Emerges as Value Opportunity Amid Utility Sector Pullback 07:34 Carlsmed and the Upcoming Reimbursement Reset 07:32 Evaluating the Risk-Reward Profile of BlackRock MuniHoldings California Quality Fund 07:29 BorgWarner Shifts Propulsion Expertise Toward Data Centers and Industrial Power 07:29 Jenoptik Reports Double-Digit Revenue Growth Amid Semiconductor Surge 08:46 Credo Technology Shares Fall Sharply Following September Earnings Report 08:35 Artificial Intelligence Dominates Market Focus Once Again 08:29 Nvidia Shares Slide as CEO Jensen Huang Resigns Following Scandal 08:25 Embraer Maintains Buy Rating Following Third-Quarter Performance 08:23 Anthropic Targets $1.4 Trillion Valuation in Upcoming Nasdaq Debut 08:20 Lowe's Positioned for Growth Amid Expanding Home Remodeling Budgets 07:39 Examining OMS Energy Technologies: Balance Sheet Strength and Growth Prospects 07:35 NextEra Energy Emerges as Value Opportunity Amid Utility Sector Pullback 07:34 Carlsmed and the Upcoming Reimbursement Reset 07:32 Evaluating the Risk-Reward Profile of BlackRock MuniHoldings California Quality Fund 07:29 BorgWarner Shifts Propulsion Expertise Toward Data Centers and Industrial Power 07:29 Jenoptik Reports Double-Digit Revenue Growth Amid Semiconductor Surge

Topic: Lineage Cell Therapeutics

Lineage Cell Therapeutics Acquires NeuroAirmid, Extends Cash Runway into 2028

🧠AI Analysis

AI Analysis15 h ago

Lineage Cell Therapeutics Acquires NeuroAirmid, Extends Cash Runway into 2028

Lineage Cell Therapeutics announced the acquisition of NeuroAirmid Therapeutics to add a Huntington's disease program, while extending its cash runway into the second qua…

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.